MedTrace Logo

Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma

NCT05227144 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2025-03-20

No results posted yet for this study

Summary

The purpose of this study is to establish the Recommended Phase 2 Dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antimyeloma activity of ORIC-533 in patients with multiple myeloma who have exhausted available treatment options

Conditions

Interventions

DRUG

ORIC-533

ORIC-533 once daily in consecutive 28-day cycles

Sponsors & Collaborators

  • ORIC Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Pratik S. Multani, MD · ORIC Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-06
Primary Completion
2025-03-03
Completion
2025-03-03
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05227144 on ClinicalTrials.gov